Literature DB >> 24255613

Health-related quality of life in hemophilia: results of the Hemophilia-Specific Quality of Life Index (Haem-a-Qol) at a Brazilian blood center.

Adriana Aparecida Ferreira1, Isabel Cristina Gonçalves Leite, Maria Teresa Bustamante-Teixeira, Camila Soares Lima Corrêa, Danielle Teles da Cruz, Daniela de Oliveira Werneck Rodrigues, Monica Calil Borges Ferreira.   

Abstract

BACKGROUND: Studies on health-related quality of life are based on the increasingly evident need for medical care not to be limited to preventing death, but to focus instead on the value of health.
OBJECTIVE: This study aimed to measure the health-related quality of life in hemophilia, using the Hemophilia- Specific Quality of Life (Haem-A-QoL) questionnaire and describe the socioeconomic characteristics and health conditions of these patients.
METHODS: The Brazilian version of the Hemophilia-Specific Quality of Life questionnaire was administered to hemophiliac adults, treated in an on-demand regime at the Juiz de Fora Regional Blood Center - HEMOMINAS Foundation. The patients were interviewed about demographic and socioeconomic data and their understanding of the questionnaire. Clinical data were collected from medical records. The Mann-Whitney U test was used for statistical analysis. The level of significance was set for p-values < 0.05. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS, version 15.0).
RESULTS: Thirty-nine patients were evaluated. The mean age was 36.8 years. 84.6% had hemophilia A; 20.5% of the patients had hemophilia classified as mild, 41% as moderate and 38.5% as severe. The records of 10.5% of the patients registered seropositivity for anti-HIV and 57.9% for anti-HCV. Target joints were detected in 69.2%. The mean total Hemophilia-Specific Quality of Life score was 35.55. 'Sports and leisure'and 'Physical health'were the most impaired dimensions and the dimension 'Relationship and partners'was the least impaired. The Hemophilia-Specific Quality of Life scores showed good discriminant validity for hemophilia severity (p-value = 0.001), HIV-infection (p-value = 0.02), HCV-infection (p-value = 0.01) and the presence of target joints (p-value < 0.001).
CONCLUSION: Health-related quality of life in hemophilia, measured by the Hemophilia-Specific Quality of Life questionnaire, was influenced by the presence of arthropathy and infectious diseases transmitted by blood products. Rehabilitation measures should be encouraged in order to improve the quality of life of these patients.

Entities:  

Keywords:  Hemophilia A; Hemophilia B; Joint diseases; Musculoskeletal diseases/etiology; Quality of life; Questionnaires

Year:  2013        PMID: 24255613      PMCID: PMC3832310          DOI: 10.5581/1516-8484.20130108

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN: 1516-8484


  13 in total

Review 1.  Musculoskeletal complications of haemophilia: the joint.

Authors:  M S Gilbert
Journal:  Haemophilia       Date:  2000-07       Impact factor: 4.287

2.  I need to pay more attention to mild haemophilia patients.

Authors:  R A Lipton
Journal:  Haemophilia       Date:  2011-02-07       Impact factor: 4.287

3.  Health status and health-related quality of life associated with hemophilia.

Authors:  Ronald D Barr; Mahassen Saleh; William Furlong; John Horsman; Julia Sek; Mohan Pai; Irwin Walker
Journal:  Am J Hematol       Date:  2002-11       Impact factor: 10.047

Review 4.  Quality of life assessment in clinical practice in haemophilia treatment.

Authors:  A Gringeri; L Mantovani; S V Mackensen
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

5.  Hemophilia-Specific Quality of Life Index (Haemo-QoL and Haem-A-QoL questionnaires) of children and adults: result of a single center from Turkey.

Authors:  Arzu Mercan; Nazan Sarper; Murat Inanir; Halil Irfan Mercan; Emine Zengin; Suar Çaki Kiliç; Ayşe Sevim Gökalp
Journal:  Pediatr Hematol Oncol       Date:  2010-09       Impact factor: 1.969

Review 6.  Evaluation of outcome of care in patients with haemophilia.

Authors:  K Beeton
Journal:  Haemophilia       Date:  2002-05       Impact factor: 4.287

7.  Clinical severity of haemophilia A: does the classification of the 1950s still stand?

Authors:  I E M Den Uijl; E P Mauser Bunschoten; G Roosendaal; R E G Schutgens; D H Biesma; D E Grobbee; K Fischer
Journal:  Haemophilia       Date:  2011-05-05       Impact factor: 4.287

8.  Comparing two measures of quality of life for children with haemophilia: the CHO-KLAT and the Haemo-QoL.

Authors:  C S Bradley; M Bullinger; P J McCusker; C D Wakefield; V S Blanchette; N L Young
Journal:  Haemophilia       Date:  2006-11       Impact factor: 4.287

9.  Challenges of patient-reported outcome assessment in hemophilia care—a state of the art review.

Authors:  Monika Bullinger; Denise Globe; Joan Wasserman; Nancy L Young; Sylvia von Mackensen
Journal:  Value Health       Date:  2009 Jul-Aug       Impact factor: 5.725

10.  Physiotherapy, rehabilitation and sports in countries with limited replacement coagulation factor supply.

Authors:  B M Buzzard
Journal:  Haemophilia       Date:  2007-09       Impact factor: 4.287

View more
  12 in total

1.  Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.

Authors:  Midori Shima; Hideji Hanabusa; Masashi Taki; Tadashi Matsushita; Tetsuji Sato; Katsuyuki Fukutake; Ryu Kasai; Koichiro Yoneyama; Hiroki Yoshida; Keiji Nogami
Journal:  Blood Adv       Date:  2017-09-27

2.  Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire.

Authors:  Chatree Chai-Adisaksopha; Mark W Skinner; Randall Curtis; Neil Frick; Michael B Nichol; Declan Noone; Brian O'Mahony; David Page; Jeffrey Stonebraker; Lehana Thabane; Mark Crowther; Alfonso Iorio
Journal:  BMJ Open       Date:  2018-08-08       Impact factor: 2.692

3.  Health Status of Persons with Hemophilia: A Pilot Survey from a Resource-Constrained Country.

Authors:  Helen C Okoye; Benedict Nwogoh; Megan Adediran; Theresa U Nwagha
Journal:  Niger Med J       Date:  2019 Mar-Apr

4.  Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Authors:  Johnny Mahlangu; Johannes Oldenburg; Michael U Callaghan; Midori Shima; Maria Elisa Mancuso; Peter Trask; Michael Recht; Claudia Garcia; Renchi Yang; Michaela Lehle; Harrison Macharia; Elina Asikanius; Gallia G Levy; Rebecca Kruse-Jarres; Sylvia von Mackensen
Journal:  Haemophilia       Date:  2019-04-24       Impact factor: 4.287

5.  "Development in well-being and social function among Danish hemophilia patients with HIV: a three-wave panel study spanning 24 years".

Authors:  Emilie B Ingvorsen; Christina Schnohr; Terkel Andersen; Lars Lehrmann; Eva Funding; Lone H Poulsen; Karen B Holm; Alex L Laursen; Jan Gerstoft; Jakob B Bjorner
Journal:  BMC Public Health       Date:  2019-12-19       Impact factor: 3.295

6.  Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Olga Katsarou; Dimitris Niakas
Journal:  Biomed Res Int       Date:  2014-05-06       Impact factor: 3.411

Review 7.  Hemophilia A in Brazil - epidemiology and treatment developments.

Authors:  Adriana Aparecida Ferreira; Isabel Cristina Gonçalves Leite; Maria Teresa Bustamante-Teixeira; Maximiliano Ribeiro Guerra
Journal:  J Blood Med       Date:  2014-09-23

8.  Bioengineering coagulation factors for improved hemophilia treatments: Comment on: the mutation F309S increases FVIII secretion in human cell line.

Authors:  Bidossessi Wilfried Hounkpe; Erich Vinicius de Paula
Journal:  Rev Bras Hematol Hemoter       Date:  2016-05-21

9.  Health-Related Quality of Life and Association With Arthropathy in Greek Patients with Hemophilia.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Dimitris Niakas; Anna Kouramba; Olga Katsarou
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

Review 10.  Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.

Authors:  Sandra Le Quellec
Journal:  Drug Des Devel Ther       Date:  2020-02-03       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.